• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Viatris Inc.

    10/25/24 4:37:27 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTRS alert in real time by email
    DEFA14A 1 d816790ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

     

    Filed by the Registrant ☒        Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐   Preliminary Proxy Statement
    ☐   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐   Definitive Proxy Statement
    ☒   Definitive Additional Materials
    ☐   Soliciting Material under §240.14a-12

    VIATRIS INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒   No fee required.
    ☐   Fee paid previously with preliminary materials.
    ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


    LOGO

    Important Notice Regarding the Availability of Proxy Materials for the

    Viatris Inc. (the “Company”) Annual Meeting of Shareholders To Be Held on December 6, 2024

    Under U.S. Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for our 2024 annual meeting of shareholders (the “2024 Annual Meeting”) are available on the Internet. Follow the instructions below to view the proxy materials and to submit your proxy and voting instructions online. The items to be voted on and location of the 2024 Annual Meeting are on the reverse side of this notice. Your vote is important!

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before submitting your proxy and voting instructions.

    To view the proxy materials, which consist of the Proxy Statement and 2023 Annual Report, request a paper or email copy of the proxy materials, and/or select a future delivery preference, please have this notice available and visit www.eproxyaccess.com/vtrs2024. You will be required to use the control number located in the shaded box below.

     

    LOGO

    After you have reviewed the proxy materials, you may submit your proxy and voting instructions over the Internet at:

    https://www.proxyvotenow.com/vtrs

    Please have this notice available when you access the voting website. You will be required to use your control number located in the shaded box above to log in and vote. Please note that submitting your proxy and voting instructions online authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned a proxy card.

    If you would like to receive a paper or email copy of the proxy materials and/or select a future delivery preference, you must do so using one of the following options:

     

    LOGO

       Internet – Go to www.eproxyaccess.com/vtrs2024 and follow the registration instructions.

    LOGO

       Telephone – Call us free of charge at 1-855-708-9771 from within the United States or Canada.

    LOGO

       E-mail – Send us an e-mail at [email protected], using the control number above as the subject line, and state whether you wish to receive a paper or e-mail copy of the proxy materials and whether your request is for this meeting only or for all future meetings.

    If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed above on or before November 29, 2024 to facilitate timely delivery.


    The 2024 Annual Meeting will be held on Friday, December 6, 2024

    at 11 a.m. Eastern Time at the DoubleTree Crystal City.

    The proposals to be voted on at the 2024 Annual Meeting are listed below along with Viatris’ Board of Directors’ (the “Board of Directors”) recommendations.

    THE VIATRIS INC. BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” EACH DIRECTOR IN ITEM 1 AND “FOR” ITEMS 2, 3 AND 4.

     

      1.

    Election of the following 12 directors, each to hold office until the 2025 annual meeting of shareholders:

     

    A. W. Don Cornwell

     

    E. Melina Higgins

     

    I. Richard Mark

    B. JoEllen Lyons Dillon

     

    F. James M. Kilts

     

    J. Mark Parrish

    C. Elisha Finney

     

    G. Harry Korman

     

    K. Scott A. Smith

    D. Leo Groothuis

     

    H. Rajiv Malik

      L. Rogério Vivaldi Coelho

     

      2.

    Approval of, on a non-binding advisory basis, the 2023 compensation of the named executive officers of the Company.

     

      3.

    Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

     

      4.

    Approval of an amendment to the Viatris Inc. 2020 Stock Incentive Plan.

    After you have reviewed the proxy materials, you may submit your proxy and voting instructions online at https://www.proxyvotenow.com/vtrs by logging in with your control number located in the shaded box on the front of this notice.

    You are entitled to vote at the 2024 Annual Meeting only if you were a shareholder of Viatris Inc. as of the close of business (5:00 p.m. Eastern Time) on October 11, 2024, which is the record date for the 2024 Annual Meeting.

    PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares of Viatris Inc. common stock you must submit your proxy and voting instructions online or request a paper or email copy of the proxy materials to receive a proxy card. Please also note that if you plan to attend the 2024 Annual Meeting, you must register in advance and provide proper identification and this notice. See the question titled “How can I attend the 2024 Annual Meeting?” on page A-2 of the Proxy Statement for information about the location, format and how to register to attend the meeting.

    Directions to the 2024 Annual Meeting: If you plan to attend our 2024 Annual Meeting in person, you can obtain directions to DoubleTree Crystal City (300 Army Navy Drive, Arlington, VA 22202) at the hotel’s website, https://www.hilton.com/en/hotels/dcaaedt-doubletree-washington-dc-crystal-city/hotel-location/.

    Get the next $VTRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTRS

    DatePrice TargetRatingAnalyst
    2/9/2026$18.00Neutral → Buy
    UBS
    1/16/2026$15.00Hold → Buy
    Argus
    12/9/2025$15.00Overweight
    Barclays
    10/15/2025$15.00Buy
    Truist
    6/6/2025$10.00Neutral
    Goldman
    7/19/2024$15.00Buy
    Jefferies
    10/23/2023$13.00 → $9.00Neutral → Underperform
    BofA Securities
    6/23/2023$11.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $VTRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Viatris upgraded by UBS with a new price target

    UBS upgraded Viatris from Neutral to Buy and set a new price target of $18.00

    2/9/26 6:59:24 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris upgraded by Argus with a new price target

    Argus upgraded Viatris from Hold to Buy and set a new price target of $15.00

    1/16/26 8:41:55 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Viatris with a new price target

    Barclays initiated coverage of Viatris with a rating of Overweight and set a new price target of $15.00

    12/9/25 8:55:06 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

    PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. In addition, Viatris will host an Investor Event on March 19, 2026, in New York City. More details regarding the event will be provided during the Co

    2/3/26 4:34:00 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Appoints Matthew J. Maletta as Chief Legal Officer

    Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period  PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in multiple leadership positions and played a key role in supporting the Company's operations, portfolio and growth initiatives, will stay on through April 1, 2026, to ensure a smooth transition

    2/3/26 8:30:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

    Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), the first country within the Viatris territories to commercialize the treatment. Future launches are planned in multiple countries over the next several years, supporting Viatris' strategy to expand access to the treatment in key markets outside of the U.S. and Europe. Inpefa is the first and only dual SGLT1/2 inhibitor approved for the treatment of heart failure. The treatment is approved in the U.S. and UAE to reduc

    1/20/26 6:59:00 AM ET
    $LXRX
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Viatris Inc.

    SCHEDULE 13G/A - Viatris Inc (0001792044) (Subject)

    2/4/26 10:56:52 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Viatris Inc.

    8-K - Viatris Inc (0001792044) (Filer)

    2/3/26 4:30:31 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Viatris Inc (0001792044) (Filer)

    12/8/25 7:00:47 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Smith Scott Andrew bought $219,740 worth of shares (22,000 units at $9.99), increasing direct ownership by 8% to 314,807 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    8/13/25 6:08:30 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Smith Scott Andrew bought $536,262 worth of shares (60,000 units at $8.94), increasing direct ownership by 26% to 292,807 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    5/14/25 6:00:11 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    10/25/24 4:30:03 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mistras Theodora converted options into 25,260 shares and covered exercise/tax liability with 14,598 shares, increasing direct ownership by 42% to 35,842 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    1/2/26 6:00:16 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Le Goff Corinne sold $72,045 worth of shares (7,032 units at $10.25), decreasing direct ownership by 17% to 35,299 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    9/12/25 6:00:21 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Enrietti Andrew

    4 - Viatris Inc (0001792044) (Issuer)

    8/19/25 6:03:14 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Financials

    Live finance-specific insights

    View All

    Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

    PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. In addition, Viatris will host an Investor Event on March 19, 2026, in New York City. More details regarding the event will be provided during the Co

    2/3/26 4:34:00 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Announces Quarterly Dividend

    PITTSBURGH, Nov. 4, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on November 3, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 15, 2025, to shareholders of record as of the close of business on November 24, 2025. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we pr

    11/4/25 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

    PITTSBURGH, Oct. 1, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report third quarter 2025 financial results on Thursday, November 6, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healt

    10/1/25 9:00:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viatris Inc.

    SC 13G/A - Viatris Inc (0001792044) (Subject)

    11/12/24 1:41:20 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Viatris Inc. (Amendment)

    SC 13G/A - Viatris Inc (0001792044) (Subject)

    2/13/24 5:17:31 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Viatris Inc.

    SC 13G - Viatris Inc (0001792044) (Subject)

    2/9/24 1:10:51 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Leadership Updates

    Live Leadership Updates

    View All

    Viatris Appoints Matthew J. Maletta as Chief Legal Officer

    Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period  PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in multiple leadership positions and played a key role in supporting the Company's operations, portfolio and growth initiatives, will stay on through April 1, 2026, to ensure a smooth transition

    2/3/26 8:30:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

    PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies. Ramsburg is an accomplished leader with more than 25 years of experience building and leading highly effective cross-functional

    1/8/26 9:05:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

    PITTSBURGH, Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate functions. The consolidation of these areas centralizes leadership of the company's digital, cultural and structural transformation initiatives and is designed to accelerate the company's ongoing strategic evolution.

    8/19/25 9:00:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care